EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ADAM10 Gene Variants in AD Patients and Their Relationship to CSF Protein Levels

Pablo Agüero-Rabes, Julián Pérez-Pérez iD, Lucía Cremades-Jimeno iD, María-Salud García-Ayllón iD, Adriana Gea-González iD, María José Sainz, Ignacio Mahillo-Fernández iD, Raquel Téllez, Blanca Cárdaba iD, Javier Sáez-Valero iD, Estrella Gómez-Tortosa iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24076113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Pablo Agüero-Rabes und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Fundación Jiménez Díaz, 28040 Madrid, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ayuda a Neurociencias de Fundación Tatiabna Pérez de Guzmán el Bueno, Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, Direcció General d'Universitat, Investigació i Ciència, GVA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ADAM10 is the main α-secretase acting in the non-amyloidogenic processing of APP. We hypothesized that certain rare ADAM10 variants could increase the risk for AD by conferring the age-related downregulation of α-secretase. The ADAM10 gene was sequenced in 103 AD cases (82% familial) and 96 cognitively preserved nonagenarians. We examined rare variants (MAF < 0.01) and determined their potential association in the AD group with lower CSF protein levels, as analyzed by means of ELISA, and Western blot (species of 50 kDa, 55 kDa, and 80 kDa). Rare variants were found in 15.5% of AD cases (23% early-onset, 8% late-onset) and in 12.5% of nonagenarians, and some were group-specific. All were intronic variants except Q170H, found in three AD cases and one nonagenarian. The 3′UTR rs74016945 (MAF = 0.01) was found in 6% of the nonagenarians (OR 0.146, p = 0.057). Altogether, ADAM10 total levels or specific species were not significantly different when comparing AD with controls or carriers of rare variants versus non-carriers (except a Q170H carrier exhibiting low levels of all species), and did not differ according to the age at onset or APOE genotype. We conclude that ADAM10 exonic variants are uncommon in AD cases, and the presence of rare intronic variants (more frequent in early-onset cases) is not associated with decreased protein levels in CSF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAged, 80 and overHumansADAM ProteinsADAM10 ProteinAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesMembrane ProteinsCerebrospinal Fluid Proteins

Stichwörter der Autor:innen

ADAM10Alzheimer’s diseaseCSF biomarkersdisintegrin metalloproteinase 10 proteingeneticsα-secretase

Substanzen

ADAM ProteinsADAM10 ProteinADAM10 protein, humanAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesMembrane ProteinsCerebrospinal Fluid Proteins

Autor:innen und Institutionen

  • Department of Neurology, Fundación Jiménez Díaz, 28040 Madrid, Spain.
  • Secugen S.L., 28040 Madrid, Spain.
  • Department of Immunology, IIS-Fundación Jiménez Díaz-UAM, 28040 Madrid, Spain.
  • Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, 03550 Alicante, Spain.
  • Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 03550 Alicante, Spain.
  • Unidad de Investigación, Hospital General Universitario de Elche, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), 46020 Valencia, Spain.

ORCID-Profile: Julián Pérez-Pérez, Lucía Cremades-Jimeno, María-Salud García-Ayllón, Adriana Gea-González, Ignacio Mahillo-Fernández, Blanca Cárdaba, Javier Sáez-Valero, Estrella Gómez-Tortosa

Förderung

  • Ayuda a Neurociencias de Fundación Tatiabna Pérez de Guzmán el Bueno
  • Instituto de Salud Carlos III (ISCIII) co-funded by the European Union
  • Direcció General d'Universitat, Investigació i Ciència, GVA
  • Generalitat Valenciana
  • Instituto de Salud Carlos III (ISCIII)
  • Ayuda a Neurociencias de la Fundación Tatiana Pérez de Guzmán el Bueno
  • FEDER funds, Spain
  • Direcció General d’Universitat, Investigació i Ciència, GVA

Zitieren

APA

Agüero-Rabes, P., Pérez-Pérez, J., Cremades-Jimeno, L., García-Ayllón, M. S., Gea-González, A., Sainz, M. J., Mahillo-Fernández, I., Téllez, R., Cárdaba, B., Sáez-Valero, J., & Gómez-Tortosa, E. (2023). ADAM10 Gene Variants in AD Patients and Their Relationship to CSF Protein Levels. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076113

Vancouver

Agüero-Rabes P, Pérez-Pérez J, Cremades-Jimeno L, García-Ayllón MS, Gea-González A, Sainz MJ, et al. ADAM10 Gene Variants in AD Patients and Their Relationship to CSF Protein Levels. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076113

BibTeX
@article{AgeroRabes2023,
  author = {Agüero-Rabes, Pablo and Pérez-Pérez, Julián and Cremades-Jimeno, Lucía and García-Ayllón, María-Salud and Gea-González, Adriana and Sainz, María José and Mahillo-Fernández, Ignacio and Téllez, Raquel and Cárdaba, Blanca and Sáez-Valero, Javier and Gómez-Tortosa, Estrella},
  title = {ADAM10 Gene Variants in AD Patients and Their Relationship to CSF Protein Levels},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24076113}
}
Kostenlos starten →